FREQUENCY THERAPEUTICS INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit – FREQ

SAN DIEGO–(BUSINESS WIRE) – Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Massachusetts county between November 16, 2020 and March 22, 2021 on behalf of the buyers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock, including (the “Class Period”). The case is entitled Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933, and is assigned to Judge William G. Young. Frequency Therapeutics’ class action lawsuit charges Frequency Therapeutics and some of its executives with violating the Securities Exchange Act of 1934. A similar lawsuit, entitled Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending the Massachusetts District.

If you have suffered significant losses and wish to serve as the lead plaintiff in Frequency Therapeutics’ class action, please provide your information by clicking here. You can also contact Attorney JC Sanchez of Robbins Geller by phone at 800 / 449-4900 or by email at [email protected]. Lead plaintiffs for Frequency Therapeutics’ class action lawsuit must be filed in court no later than August 2, 2021.

CASE CLAIM: Frequency Therapeutics’ class action alleges that Frequency Therapeutics and its chief executive officer, Defendant David L. Lucchino, learned shortly after the Phase FX-322 2a trial began that the Phase 2a trial results were not noticeable difference between -322 and the placebo. Frequency Therapeutics ‘class action lawsuit alleges that Frequency Therapeutics’ stock price remained artificially inflated, but Defendant Lucchino sold over 350,000 shares in Frequency Therapeutics and pocketed over $ 10.5 million.

On March 23, 2021, Frequency Therapeutics released deeply disappointing Phase 2a interim results showing that patients with mild to moderate sensorineural hearing loss showed no improvements in hearing measurements compared to placebo. Because of this news, Frequency Therapeutics’ stock price fell nearly 78%, which harmed investors.

LEAD ACTION: The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Frequency Therapeutics common stock during the class action period to seek appointment as the lead plaintiff in Frequency Therapeutics’ class action. A lead plaintiff is usually the applicant with the greatest financial interest in the legal protection sought by the alleged class, which is also typical and appropriate for the alleged class. A lead plaintiff is acting on behalf of all the other group members in directing the Frequency Therapeutics class action. The lead plaintiff can select a law firm of their choice to bring the Frequency Therapeutics class action lawsuit. An investor’s ability to participate in a possible future collection of Frequency Therapeutics’ class action lawsuits does not depend on whether they are the lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm serving investors in securities class actions. Robbins Geller’s attorneys have achieved many of the largest shareholder reclaims in history, including the largest securities class action of all time – Lit 7.2 billion. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first, for getting $ 1.6 billion back for investors last year, more than double the amount recovered from any other securities plaintiff firm. Please visit https://www.rgrdlaw.com/firm.html for more information.

Lawyer advertising.

Past results do not guarantee future results.

Services can be performed by lawyers in any of our offices.

Comments are closed.